Clinical Trials Logo

Clinical Trial Summary

High-risk precancerous cervical lesions are divided into stage 2 and 3 cervical intraepithelial neoplasia (CIN 2 and 3). CIN 3 represents a direct pre-stage of invasive cancer, has a high rate of progression and a high degree of agreement with the final histological diagnosis. In CIN 2 lesions, the rate of agreement with the final histological diagnosis is lower and the rate of spontaneous regression is higher. Due to the higher rate of regression and possible complications after excisional treatment, conservative active monitoring can be considered in selected young CIN 2 patients. A recent meta-analysis reported a high rate of spontaneous clinical regression of CIN 2, particularly in women under 30 years old. There are currently no prospectively validated prognostic biomarkers to determine which CIN 2 will progress to higher grade and which will regress to lower grade of change. Recent research has studied HPV methylation and microbiome analysis as biomarkers. A number of studies have shown that host cell DNA methylation levels in cervical scrapes increase with underlying cervical disease severity and are highest in cervical cancer. DNA methylation involves the covalent binding of a methyl group to the 5´ position of a cytosine molecule in CpG dinucleotides. Besides global hypomethylation, the overall loss of methylation during carcinogenesis, resulting in chromosomal instability, and the silencing of tumour suppressor genes by local hypermethylation of CpG-rich promoter regions contribute to cancer development. Gene promoter methylation can be easily accessed by sensitive, quantitative methylation-specific PCR providing an objective test outcome. The aim of this study was to determine the effect of the methylation rate of two suppressor genes- FAM19A4 and hsa-mir-124 on the rate of CIN 2 regression, persistence or progression in women younger than 36 years (≤35 years old).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05624827
Study type Interventional
Source University Medical Centre Maribor
Contact Milena Miklus, MD
Phone +386 2 321 2178
Email milena.rmus4@gmail.com
Status Recruiting
Phase N/A
Start date September 1, 2021
Completion date May 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT03642574 - Preimplantation DNA Methylation Test (PIMT) in ART N/A
Completed NCT03787849 - Epigenetics in PostOperative Pediatric Emergence Delirium N/A
Recruiting NCT05442125 - First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization N/A
Completed NCT05085847 - Effects of Mindfulness-based Intervention on Epigenetic Mechanisms, Cognition Function, Stress Response, and Well-being N/A
Recruiting NCT04651946 - Cell-free DNA Methylation for Epithelial Ovarian Cancer Phase 2
Recruiting NCT04646954 - DNA Methylation Testing for the Screening of Uterine Cervical Lesion Phase 3
Recruiting NCT03961191 - DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study
Not yet recruiting NCT05779904 - Methylation, mIcrobiome, NUtritional sTatus, and dEvelopment of Stunted Children
Recruiting NCT05791149 - Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity N/A
Recruiting NCT05801263 - ctDNA Methylation for Epithelial Ovarian Cancer
Recruiting NCT05801276 - ctDNA Methylation for Detecting Ovarian Cancer
Recruiting NCT05290415 - Host DNA Methylation for Endometrial Cancer Screening
Recruiting NCT05290428 - DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening
Recruiting NCT05290922 - DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening
Recruiting NCT03960879 - DNA Methylation for Screening Uterine Cervical Lesions
Recruiting NCT05737953 - Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
Recruiting NCT06140992 - PaCIFiC-CUP Classifies Cancer of Unknown Primary
Completed NCT02032628 - DNA Methylation and Cancer Prevention: Duration and Intensity of Exercise N/A
Completed NCT04568512 - DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture N/A
Completed NCT03227003 - DNA Methylation and 1-C Metabolism Nutrient Intake N/A